Home › NDC Lookup › RxCUI directory › RxCUI 2003797

{14 (lamotrigine 100 MG Oral Tablet [Subvenite]) / 84 (lamotrigine 25 MG Oral Tablet [Subv... — RxCUI 2003797

RxNorm drug concept · Brand name pack
RxCUI 2003797 Brand name pack · BPCK ● Current RxNorm concept 7 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2003797
Official name{14 (lamotrigine 100 MG Oral Tablet [Subvenite]) / 84 (lamotrigine 25 MG Oral Tablet [Subvenite]) } Pack [Subvenite Green (for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone and Not Taking Valproate)]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asSubvenite Green Kit (for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone and Not Taking Valproate); Subvenite Starter Kit Green 25 MG (84), 100 MG (14) 98 Count
FDA products mapped7
Package NDCs mapped9
Reported Medicaid activity (SDUD)191 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lamotrigine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats epilepsy, helping control certain seizure types. Some forms, like tablets, chewables and orally disintegrating tablets, are also used to delay mood episodes in bipolar I...
  • Lamotrigine can cause serious, even life-threatening skin reactions, mostly in the first 2 to 8 weeks. We can't tell which rashes are dangerous, so call your doctor right away abou...
  • Take it by mouth exactly as prescribed, increasing slowly as planned. Skipping ahead raises rash risk. Extended-release tablets are once daily and must be swallowed whole. Food doe...
  • Please don't stop on your own. Stopping suddenly can trigger withdrawal seizures. Your doctor will taper you off over at least 2 weeks.
📖 Read our full Lamotrigine guide →

🕸️ Concept Web — How {14 (lamotrigine 100 MG Oral Tablet [Subvenite])... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {14 (lamotrigine 100 MG Oral Tablet [Subvenite]) / 84 (lamotrigine 25 MG Oral Tablet [Subvenite]) } Pack [Subvenite Green (for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone and Not Taking Valproate)] RxCUI 2003797

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lamotrigine 28439
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Subvenite 2001501
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lamotrigine Oral Tablet 372567
    • Lamotrigine Oral Product 1162535
    • Lamotrigine Pill 1162536
    • Lamotrigine Oral Tablet [Subvenite] 2001503
    • Subvenite Oral Product 2001504
    • Subvenite Pill 2001505
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 8

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

7 products · 9 package NDCs
9 package NDCs map to RxCUI 2003797 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
69102-0150-06 100 TABLET in 1 BOTTLE (69102-150-06) SUBVENITE OWP Pharmaceuticals, Inc. 2018-03-10
69102-0300-01 7 BLISTER PACK in 1 PACKAGE, COMBINATION (69102-300-01) / 1... SUBVENITE OWP Pharmaceuticals, Inc. 2018-04-14
69102-0301-01 100 TABLET in 1 BOTTLE (69102-301-01) SUBVENITE OWP Pharmaceuticals, Inc. 2018-03-10
69102-0301-02 6600 TABLET in 1 BOTTLE (69102-301-02) SUBVENITE OWP Pharmaceuticals, Inc. 2018-03-10
69102-0306-01 35 BLISTER PACK in 1 BLISTER PACK (69102-306-01) / 1 KIT in... SUBVENITE OWP Pharmaceuticals, Inc. 2018-04-14
69102-0312-01 14 BLISTER PACK in 1 PACKAGE, COMBINATION (69102-312-01) /... SUBVENITE OWP Pharmaceuticals, Inc. 2018-04-14
69102-0319-01 100 TABLET in 1 BOTTLE (69102-319-01) SUBVENITE OWP Pharmaceuticals, Inc. 2018-03-10
69102-0319-02 2500 TABLET in 1 BOTTLE (69102-319-02) SUBVENITE OWP Pharmaceuticals, Inc. 2018-03-10
69102-0320-01 100 TABLET in 1 BOTTLE (69102-320-01) SUBVENITE OWP Pharmaceuticals, Inc. 2018-03-10
Observed labelers: OWP Pharmaceuticals, Inc. (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.